BJH: Switching to Avambopag after Eltrombopag or Romigrastim in Adults with Immune Thrombocytopenia: A Multicenter US Study

Patients with immune thrombocytopenia (ITP) may respond to one thrombopoietin receptor agonist (TPO-RA) but not another
.

There are limited data available describing the outcomes of patients who switched from romiprostim or eltrombopag to avafambopa, a newer oral TPO-RA

Patients with immune thrombocytopenia (ITP) may respond to one thrombopoietin receptor agonist (TPO-RA) but not another

Figure: Median platelet counts for each patient before switching (during romiprostim or eltrombopag treatment) and after switching to avambopag
.

For each patient, the median platelet count was the median of the last three platelet counts measured while receiving the drug

Figure: Median platelet counts for each patient before switching (during romiprostim or eltrombopag treatment) and after switching to avambopag

We conducted a retrospective observational study of adults with ITP who were converted from eltrombopag or romipprotine to avantgarde at four tertiary ITP referral centers in the United States

Abbreviations: PC, platelet count
.

Abbreviations: PC, platelet count
.

Across all patients, the median platelet count was 44 × 109/l for eltrombopag or romiprostim vs 113 × 109/l for avantgarde (p < 0.
0001); Among patients who were switched to romiplastine/eltrombopag after failure of trombopag, romiplastine/eltrombopag was 28 × 109/l versus 88 × 109/l for avant- 0.
025)
.

Fifty-seven percent of patients who received concomitant ITP medication before the switch discontinued after the switch, and 63% of these patients received chronic corticosteroids

Across all patients, the median platelet count was 44 × 109/l for eltrombopag or romiprostim vs 113 × 109/l for avantgarde (p < 0.

In a heavily pretreated chronic ITP population, avambopag was effective after treatment with romiplostim or eltrombopag, with high response rates even in patients with an inadequate response to prior TPO-RA

Original source:

Original source:

Al-Samkari, HP ,Jiang, D ,Gernsheimer, T ,Liebman, H ,Lee, S ,Wojdyla, M ,Vredenburg, M ,Cuker, A .

Al-Samkari, HP ,  Jiang, D ,  Gernsheimer, T ,  Liebman, H ,  Lee, S ,  Wojdyla, M ,  Vredenburg, M ,  Cuker, A .
  Adults with immune thrombocytopenia who switched to avatrombopag following prior treatment with eltrombopag or romiplostim: A multicentre US study .
  Br J Haematol .
  2022 ;  00 :  1 –  8.
Al-Samkari, HP , Jiang  , D ,  Gernsheimer, T ,  Liebman, H ,  Lee, S ,  Wojdyla, M,  Vredenburg, M ,  Cuker, A.
Adults  with immune thrombocytopenia who switched to avatrombopag following prior treatment with eltrombopag or romiplostim: A multicentre US study .
  Br J Haematol .
  2022 ;  00 :  1 –  8.
Leave a comment here